🎯 Drug Targets

Browse 16 drug targets with druggability analysis, composite scores, and clinical context

16
Targets
0
High Druggability
0.48
Avg Score
15
Target Classes
Druggability Distribution
High: 0Medium: 0Low: 16Unknown: 0
Avg druggability score: 0.298
Clinical Pipeline
Approved: 3Phase III: 0Phase II: 7Phase I: 6Preclinical: 0
Total compounds: 19 · Approved: 3
Filtered by: class=signaling_protein, druggability=Low — 16 results
MIRO1 Mitochondrial Rho GTPase 1 Phase 2
Signaling Protein Low Druggability
Score
0.63
Drug.
0.29
Safety
0.40
Drugs
4
Hyps
5
Papers
29
MIRO1-targeting drugs modulate GTPase activity to enhance mitochondrial transport along axons and improve mitochondrial quality control through selective autophagy. By regulating MIRO1's interaction with kinesin motor proteins and PINK1-mediated mitophagy, these compounds restore energy homeostasis and reduce neuronal stress in neurodegenerative diseases.
C1Q Complement C1q Phase 4
Signaling Protein Low Druggability
Score
0.62
Drug.
0.36
Safety
0.45
Drugs
1
Hyps
58
Papers
22
Complement cascade inhibitor or antibody-mediated neutralization
STING1 Stimulator of interferon genes protein 1 Phase 2
Signaling Protein Low Druggability
Score
0.60
Drug.
0.40
Safety
0.40
Drugs
2
Hyps
1
Papers
22
Small molecule agonists or antagonists of cGAS-STING pathway activation
RAB27A Ras-related protein Rab-27A Phase 2
Signaling Protein Low Druggability
Score
0.59
Drug.
0.35
Safety
0.40
Drugs
1
Hyps
1
Papers
28
RAB27A inhibitors would block GTP binding or GTPase activity, preventing the recruitment of effector proteins required for vesicular trafficking and exosome biogenesis. This would reduce the release of extracellular vesicles and potentially modulate intercellular communication in disease states involving excessive exosome-mediated signaling or pathological cargo transfer.
C1QA Complement C1q A Chain Phase 2
Signaling Protein Low Druggability
Score
0.58
Drug.
0.41
Safety
0.45
Drugs
1
Hyps
5
Papers
44
Complement cascade inhibitor or antibody-mediated neutralization
ANXA1 Annexin A1 Phase 4
Signaling Protein Low Druggability
Score
0.53
Drug.
0.41
Safety
0.60
Drugs
1
Hyps
1
Papers
25
Calcium-dependent phospholipid binding protein modulator
SYNCRIP Heterogeneous nuclear ribonucleoprotein Q Phase 2
Signaling Protein Low Druggability
Score
0.50
Drug.
0.32
Safety
0.40
Drugs
2
Hyps
1
Papers
30
Small molecule or antisense-based inhibitors would disrupt SYNCRIP's RNA-binding capability, reducing its ability to facilitate mRNA transport and local protein synthesis, potentially modulating disease pathways in neurological disorders or cancers where SYNCRIP dysfunction is implicated.
PYCARD Apoptosis-associated speck-like protein containing Phase 2
Signaling Protein Low Druggability
Score
0.50
Drug.
0.35
Safety
0.40
Drugs
1
Hyps
1
Papers
0
PYCARD acts as a critical adaptor protein in inflammasome activation, facilitating pro-inflammatory caspase-1 recruitment and subsequent IL-1β/IL-18 processing, which contributes to neuroinflammatory processes in neurodegenerative conditions like Alzheimer's and Parkinson's disease. Its protein-protein interaction domains mediate inflammatory signal transduction, potentially amplifying neuronal damage through excessive immune response activation.
CELL-TYPE-SPECIFICESSENTIALGENES CELL-TYPE-SPECIFICESSENTIALGENES Phase 1
Signaling Protein Low Druggability
Score
0.48
Drug.
0.30
Safety
0.50
Drugs
0
Hyps
1
Papers
12
Prioritized from 1 SciDEX hypotheses, including: Context-Dependent CRISPR Activation in Specific Neuronal Subtypes
RELN Reelin Phase 4
Signaling Protein Low Druggability
Score
0.48
Drug.
0.33
Safety
0.50
Drugs
4
Hyps
1
Papers
31
Drugs targeting RELN would primarily work by enhancing reelin expression or signaling through its receptors (VLDLR and ApoER2) to promote neuronal migration, synaptic plasticity, and cognitive function. Alternatively, pathway modulators could enhance downstream signaling cascades (Dab1-mediated pathways) to compensate for reelin deficiency or dysfunction.
LAMP2B LAMP2B Phase 1
Signaling Protein Low Druggability
Score
0.41
Drug.
0.40
Safety
0.30
Drugs
0
Hyps
1
Papers
7
Prioritized from 1 SciDEX hypotheses, including: Microglia-Derived Extracellular Vesicle Engineering for Targeted Mitochondrial Delivery
DISEASE-CAUSINGMUTATIONSWITHINTEGRATEDREPORTERS DISEASE-CAUSINGMUTATIONSWITHINTEGRATEDREPORTERS Phase 1
Signaling Protein Low Druggability
Score
0.36
Drug.
0.20
Safety
0.20
Drugs
0
Hyps
1
Papers
7
Prioritized from 1 SciDEX hypotheses, including: Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring
SYNTHETICFUSIONPROTEINS SYNTHETICFUSIONPROTEINS Phase 1
Signaling Protein Low Druggability
Score
0.36
Drug.
0.10
Safety
0.20
Drugs
0
Hyps
1
Papers
7
Prioritized from 1 SciDEX hypotheses, including: Synthetic Biology Approach: Designer Mitochondrial Export Systems
PITX3 PITX3 Phase 1
Signaling Protein Low Druggability
Score
0.35
Drug.
0.10
Safety
0.30
Drugs
0
Hyps
1
Papers
7
Prioritized from 1 SciDEX hypotheses, including: Programmable Neuronal Circuit Repair via Epigenetic CRISPR
NEURONALIDENTITYTRANSCRIPTIONFACTORS NEURONALIDENTITYTRANSCRIPTIONFACTORS Phase 1
Signaling Protein Low Druggability
Score
0.35
Drug.
0.10
Safety
0.30
Drugs
0
Hyps
1
Papers
7
Prioritized from 1 SciDEX hypotheses, including: Programmable Neuronal Circuit Repair via Epigenetic CRISPR
PVALB Parvalbumin Phase 2
Signaling Protein Low Druggability
Score
0.33
Drug.
0.34
Safety
0.30
Drugs
2
Hyps
1
Papers
0
No known druggable mechanism